European Commission approves Merck KEYTRUDA as a HNSCC treatment
Category: #health  By Saipriya Iyer  Date: 2019-11-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

European Commission approves Merck KEYTRUDA as a HNSCC treatment

Merck, a renowned American pharmaceutical firm and one of the largest pharmaceutical companies in the world reportedly announced the approval of KEYTRUDA by European Commission.

Merck anti-PD-1 therapy, has been approved in combination with 5-fluorouracil (5-FU) and platinum chemotherapy or as a monotherapy, for the first-line therapy of patient suffering from unresectable or metastatic recurrent HNSCC (head and neck squamous cell carcinoma) whose tumors express PD-L1 ([CPS] ≥1 combined positive score).

The KEYTRUDA approval enables marketing of the same as monotherapy as well as combination regimen across all 28 EU member states and also in Norway, Iceland and Lichtenstein.

The European Commission approved KEYTRUDA on the basis of outcomes from pivotal KEYNOTE-048 Phase 3 study, in which KEYTRUDA, in comparison to the standard therapy (cetuximab with cisplatin plus 5-FU or carboplatin), showcased a substantial improvement in OS (overall survival) as monotherapy and together with chemotherapy in people whose tumors showed PD-L1 (CPS ≥1).

Professor Kevin Harrington, the KEYNOTE-048 investigator, consultant clinical oncologist of The Royal Marsden NHS Foundation Trust, professor of the biological cancer therapies in The Institute of Cancer Research at London stated that this tumor is particularly debilitating as it could affect a patient’s appearance by being conspicuously visible and impact their day-to-day functions like speaking and eating.

Understanding the heavy demand for new therapies, the company is encouraged by the KEYTRUDA approval in the EU. It would now enable patients to receive treatment with immunotherapy earlier during the course of the treatment.   

Vice President of clinical research at Merck Research Laboratories, Dr. Jonathan Cheng stated that KEYTRUDA has now become the first-in-class anti-PD-1 therapy option within the first setting for unresectable or metastatic recurrent HNSCC. This cancer has been treated in the same manner across the EU for over a decade.

Cheng further added that European Commission approval highlights the company’s commitment to revolutionizing the way this fatal disease is treated across the world.

Source credit: https://www.mrknewsroom.com/news-release/oncology/european-commission-approves-two-new-regimens-mercks-keytruda-pembrolizumab-fi



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...